Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
Biogen Idec and Genentech announce restructuring of anti-CD20 collaboration agreement
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects.
Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)
Zist Daru, ZIFERON
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report.

Pages